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Abstract 
 
Blood-derived endothelial colony-forming cells (ECFCs) have robust vasculogenic potential that 
can be exploited to bioengineer long-lasting human vascular networks in vivo. However, 
circulating ECFCs are exceedingly rare in adult peripheral blood. Because the mechanism by 
which ECFCs are mobilized into circulation is currently unknown, the reliability of peripheral 
blood as a clinical source of ECFCs remains a concern. Thus, there is a need to find alternative 
sources of autologous ECFCs. Here we aimed to determine whether ECFCs reside in the 
vasculature of human white adipose tissue (WAT) and to evaluate if WAT-derived ECFCs 
(watECFCs) have equal clinical potential to blood-derived ECFCs. We isolated the complete 
endothelial cell (EC) population from intact biopsies of normal human subcutaneous WAT by 
enzymatic digestion and selection of CD31+ cells. Subsequently, we extensively compared 
WAT-derived EC phenotype and functionality to bonafide ECFCs derived from both umbilical 
cord blood and adult peripheral blood. We demonstrated that human WAT is indeed a 
dependable source of ECFCs with indistinguishable properties to adult peripheral blood ECFCs, 
including hierarchical clonogenic ability, large expansion potential, stable endothelial phenotype, 
and robust in vivo blood vessel-forming capacity. Considering the unreliability and low rate of 
occurrence of ECFCs in adult blood and that biopsies of WAT can be obtained with minimal 
intervention in an ambulatory setting, our results indicate WAT as a more practical alternative to 
obtain large amounts of readily available autologous ECFCs for future vascular cell therapies. 
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Introduction 
Future vascular cell therapies and tissue engineering applications will likely rely on having a 
robust, clinically suitable source of autologous endothelial cells (ECs). The discovery of highly 
proliferative endothelial colony-forming cells (ECFCs) in human peripheral blood created a 
promising opportunity to non-invasively obtain large quantities of readily available ECs [1-3]. 
Indeed, studies have shown that blood-derived ECFCs have robust vasculogenic potential that 
can be exploited to bioengineer long-lasting, functional human vascular networks in vivo [3-7]. 
 
However, it is well recognized that while ECFCs are abundant in umbilical cord blood 
(cbECFCs), they are exceedingly rare in adult peripheral blood (pbECFCs) [2,8,9]. Yoder et al. 
estimated the frequency of pbECFC colonies as 0.017 per million blood mononuclear cells 
(MNC) in healthy adults, which is approximately 15-fold lower than in umbilical cord blood [9]. 
This low occurrence has created uncertainty around adult peripheral blood as a source of ECs. 
In fact, there are increasingly more studies recognizing absence of pbECFCs in a substantial 
proportion (27-31%) of healthy adult subjects [10-12]. This apparent lack of pbECFCs has also 
been described in non-healthy subjects, including patients with coronary artery disease (46%) 
[11] and age-related macular degeneration (28%) [12]. Currently, the mechanism by which 
pbECFCs are mobilized into circulation, and how this process is modulated with age, in health 
and disease, is completely unknown; thus the reliability of peripheral blood as a source of 
ECFCs remains a concern. 
 
For decades, harvesting ECs from healthy blood vessels has been largely dismissed as an 
option  with  broad  clinical  future  because,  apart  from  creating  site  morbidity,  “mature”  ECs  were 
thought to have limited replicative capacity. However, studies have shown that ECs derived 
from the wall of some blood vessels can achieve a significant number of population doublings in 
culture (30-40 PD), including those isolated from the umbilical vein, aorta, carotid artery, and 
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skin microvasculature [13,14]. This replicative capacity is similar to that reported for circulating 
pbECFCs [2,3,15]. Moreover, Ingram et al. demonstrated that both the aorta and the umbilical 
vein contain a complete hierarchy of highly proliferative ECs with equal colony-forming ability to 
blood-derived ECFCs [16], which suggested the actual vascular wall as a possible source of 
circulating ECFCs [17]. Whether ECFCs reside in the vasculature of all human tissues remains 
uncertain. Certainly, ECs can be obtained from tissues such as white adipose tissue (WAT) 
[18,19], but whether these ECs have similar clinical potential to blood-derived ECFCs has not 
been rigorously determined. Here, we examined the potential of human subcutaneous WAT as 
a source of ECFCs and compared it to both umbilical cord and adult peripheral blood. 
 
Methods 
 
Isolation of ECFCs and MSCs from WAT 
Normal discarded subcutaneous WAT samples (n=5) were obtained during a clinically-indicated 
procedure in accordance with an Institutional Review Board-approved protocol. WAT samples 
were washed, minced and enzymatically (collagenase and dispase) digested for 1h at 37°C. 
The stromal vascular fraction (SVF) was obtained after removal of mature adipocytes by 
centrifugation (450xg for 10 min) and the lysis of erythrocytes with ammonium chloride solution 
[20]. watECFCs were purified by magnetic activated cell sorting (MACS) using CD31-coated 
magnetic beads (Dynalbeads; Invitrogen, Grand Island, NY). CD31-selected WAT-derived 
ECFCs (referred to as watECFCs) were cultured on 1% gelatin-coated plates using ECFC-
medium: EGM-2 (except for hydrocortisone; Lonza, Walkersville, MD) supplemented with 20% 
FBS, 1x glutamine-penicillin-streptomycin (GPS; Invitrogen, Carlsbad, CA). WAT-derived 
mesenchymal stem cells (MSCs) (referred to as watMSCs) were obtained from the CD31- cell 
fraction of the SVF and were cultured onto non-coated plates using MSC-medium: MSCGM 
Mesenchymal Stem Cell Medium BulletKit (basal media and SingleQuots; Lonza), 
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supplemented with 10 % FBS, 1xGPS, and 10 ng/mL of FGF-2 (R&D Systems, Minneapolis, 
MN). Human ECFCs were isolated from both umbilical cord blood (cbECFCs) and adult 
peripheral blood (pbECFCs), as previously described [4]. Human MSCs were isolated from 
bone marrow aspirates (bmMSCs), as previously described [4].  
 
Expansion potential of watECFCs 
watECFCs were expanded for 50 days. All passages were performed by plating the cells onto 
1% gelatin-coated tissue culture plates at 5x103 cell/cm2 using ECFC-medium. Medium was 
refreshed every 2 to 3 days and cells were harvested by trypsinization and replated in the same 
culture conditions for the next passage. Cumulative values of total cell number were calculated 
by counting the cells at the end of each passage using a hemocytometer. 
 
Endothelial colony-forming assay 
For Passage 2 (P2) ECFCs were culture for 10 days at clonal density (200 cell/60 cm2; 600 cells 
plated; n=3 per ECFC type) onto 1% gelatin-coated plates using ECFC-medium. Medium was 
refreshed every 4 days. At day 10, colonies containing 8 or more cells (i.e., at least 3 divisions) 
were scored under a fluorescence microscope after DAPI staining of the nuclei. Endothelial 
phenotype was confirmed by binding of rhodamine-labeled Ulex Europaeus Agglutinin I (UEA-1; 
1:100; Vector Laboratories, Burlingame, CA) using a fluorescent microscope. Colonies were 
categorized into large (>300 cells), medium (100-300 cells) and small (8-100 cells) size. The 
number of cells in each colony was quantified under a fluorescent microscope after DAPI 
staining using ImageJ analysis software (NIH, Bethesda, MD, USA). 
 
Phenotypical and functional characterization of ECFCs and watMSCs 
The rest of the phenotypic and functional assays that were used to characterize watECFCs and 
watMSCs in vitro are detailed in the online Supplemental Methods. 
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in vivo vasculogenic assay 
Six-week-old athymic nu/nu mice were purchased from Massachusetts General Hospital 
(Boston,  MA).  Mice  were  housed  in  compliance  with  Boston  Children’s  Hospital  guidelines, and 
all animal-related protocols were approved by the Institutional Animal Care and Use Committee. 
Vasculogenesis was evaluated in vivo using our xenograft model as previously described [21]. 
Briefly, ECFCs and MSCs (2x106 total; 2:3 ECFC/MSC ratio)  were   resuspended   in   200  μl   of  
collagen/fibrin–based solution (3 mg/mL of bovine collagen, 30 ug/mL of human fibronectin, 
25mM HEPES, 10% 10x DMEM, 10% FBS, and 3 mg/mL of fibrinogen, pH neutral). Before cell 
injection, 50 uL of 10 U/mL thrombin was subcutaneously injected. All experiments were carried 
out in 4 mice.  
 
Histology and immunohistochemistry 
Implants were removed from euthanized mice, fixed in 10% buffered formalin overnight, 
embedded in paraffin, and sectioned (7-μm-thick). Hematoxylin and eosin (H&E) stained 
sections were examined for the presence of blood vessels containing red blood cells. For 
immunohistochemistry, sections were deparaffinized, and antigen retrieval was carried out by 
heating the sections in Tris-EDTA buffer (10 mM Tris-Base, 2 mM EDTA, 0.05% Tween-20, pH 
9.0). The sections were blocked for 30 min in 5-10% blocking serum and incubated with primary 
antibodies for 1h at RT. The following primary antibodies were used: mouse anti-human CD31 
(1:50; DakoCytomation, M0823 Clone JC70A), mouse anti-human   α-smooth  muscle   actin   (α-
SMA; 1:200; Sigma-Aldrich, A2547 Clone 1A4), and mouse IgG (1:50; DakoCytomation). 
Horseradish peroxidase-conjugated mouse secondary antibody (1:200; Vector Laboratories) 
and   3,3’-diaminobenzidine (DAB) were used for detection of hCD31, followed by hematoxilin 
counterstaining and Permount mounting. Fluorescent staining were performed using rhodamine-
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conjugated UEA-1 (20 µg/mL) and FITC-conjugated secondary antibodies (1:200; Vector 
Laboratories) followed by DAPI counterstaining.  
 
Microvessel density 
Microvessel density was reported as the average number of erythrocyte-filled vessels 
(vessels/mm2) in sections from the middle of the implants as previously described [3]. The entire 
area of each section was analyzed. Values reported for each experimental condition correspond 
to mean ± S.D. obtained from four individual mice.  
 
Quantification of lumenal engraftment of ECFCs 
Rhodamine-conjugated UEA-1 (100 uL; 1 mg/mL in normal saline) was intravenously injected 
into the tail vein of implant-bearing mice 10 min before harvesting the implants at day 8. 
Implants were removed from euthanized mice, enzymatically (collagenase and dispase) 
digested for 1 h at 37°C, and the retrieved cells analyzed by flow cytometry (FC) after incubation 
with PerCP-conjugated anti-mouse CD45 (1:100; BD Biosciences), APC-conjugated anti-human 
CD90 (1:100; BD Biosciences), and FITC-conjugated anti-human CD31 antibodies (1:100; BD 
Biosciences). ECFCs in each implant were identified as mCD45-/hCD31+ cells. Perfused ECFCs 
were identified as mCD45-/hCD31+/UEA-1+ cells. 
 
Statistical analysis 
Data were expressed as mean ± S.D. Comparisons between groups were performed by 
ANOVA   followed   by   Tukey’s   multiple   post-test analysis using Prism Version 4 software 
(GraphPad). P<0.05 was considered statistically significant. 
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Results 
 
Human WAT is a dependable source of proliferative ECFCs 
Small biopsies of WAT can be obtained with minimal intervention, without liposuction, in an 
ambulatory, office-based setting. To reproduce this prospective way of sampling, intact 
specimens of normal subcutaneous WAT (1 g) were surgically excised with minimal tissue 
disruption. WAT samples were then minced, enzymatically digested and the SVF obtained 
(Figure 1A). Using CD31-coated magnetic beads, ECs were separated (refereed to as 
watECFCs) and grew up as colonies after one week in culture (Figure 1B). EC colonies were 
left to merge and grow until confluence (Figure 1C) and were then routinely subcultured. This 
methodology was reliable and watECFCs were isolated in all WAT samples processed (5/5). 
watECFCs were serially passaged (up to P7) to determine their expansion potential. We 
obtained 108 watECFCs in approximately 25 days (P3) and as much as 4x109 watECFCs in 40 
days (P6) (Figure 1D).  
 
The presence of highly proliferative, colony-forming cells was examined at clonal density (200 
cells/60 cm2). This evaluation was carried out at P2 to avoid excessive culture-mediated 
selection of highly proliferative cells. We found that 7% of watECFCs gave rise to visible 
independent colonies (>3 cell divisions), which was significantly lower than in cbECFCs (16%) 
and pbECFCs (15%) (Figure 1F). watECFCs had a hierarchical distribution of cells with different 
clonal proliferative ability (Figure 1G), which is consistent with previous observations on blood-
derived ECFCs [2]. The percentage of medium-size (100-300 cells) colonies was significantly 
higher in pbECFCs (8%) than in watECFCs (2%). However, the percentage of highly-
proliferative (>300 cells) colonies was statistically similar (p>0.05) in cbECFCs (2.3%), 
pbECFCs (0.3%), and watECFCs (0.1%). Taken together, we demonstrated that WAT is a 
particularly dependable source of ECFCs with hierarchical clonogenic ability. 
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Robust endothelial phenotype of watECFCs 
To ensure bonafide endothelial phenotype, we extensively interrogated cells in culture (Figure 2 
and online Supplemental Figure 1). All watECFCs displayed typical cobblestone-like 
morphology and expressed the EC markers CD31 and VE-cadherin in cell-cell borders and von 
Willebrand factor (vWF) in a punctuate pattern in the cytoplasm (Figure 2A). With respect to 
purity, FC showed uniform expression of CD31 (>96%) as well as negligible presence of either 
mesenchymal (CD90+) or hematopoietic (CD45+) cells (Figure 2B). The positive expression of 
EC markers and lack of mesenchymal markers was confirmed by qRT-PCR: all three ECFCs 
(cbECFCs, pbECFCs, watECFCs) had abundant mRNA copies for CD31, vWF, VE-Cadherin, 
VEGFR-2, and eNOS (normalized to 18S rRNA abundance), but not for CD90 and PDGFR-β  
(Figure 2C). Human mesenchymal stem cells (MSCs) from both bone marrow and WAT 
(referred to as bmMSCs and watMSCs) served as non-endothelial controls. Additionally, as 
expected for human ECs, watECFCs showed specific affinity for the binding of UEA-1 lectin to 
their surface (Figure 2D) and for uptake of acetylated low density lipoproteins (Ac-LDL) (Figure 
2E). 
 
The characterization of watECFCs was extended to several assays that confirmed endothelial 
functionality in vitro. watECFCs were responsive (proliferation and migration) to VEGF-A (10 
ng/mL) and FGF-2 (1 ng/mL), and there were no significant difference between watECFCs, 
pbECFC, and cbECFCs in their response towards these angiogenic factors (Figure 3A-B). 
watECFCs were also able to assemble into capillary-like structures onto Matrigel (Figure 3C), 
and the extent of tube formation was statistically similar to both pbECFCs and cbECFCs. 
Finally, watECFCs were able to up-regulate the expression of leukocyte adhesion molecules (E-
selectin, ICAM-1) upon exposure to the inflammatory cytokine tumor necrosis factor-alpha 
(TNF-α;;  10  ng/mL),  which  resulted  in  a  subsequent  increase  in  leukocyte  binding  (Figure  3D-E). 
 10 
The capacity to up-regulate leukocyte adhesion molecules was present in all three ECFC 
groups (Figure 3D-E and online Supplemental Figure 1), although more leukocytes bound 
cbECFCs and pbECFCs than watECFCs after TNF-α  stimulation.  Collectively,   this  exhaustive  
characterization revealed that (1) watECFCs were undoubtedly ECs, and (2) WAT- and blood-
derived ECFCs are phenotypically highly similar. 
 
Modulation of MSC smooth muscle differentiation 
Another property of bonafide ECs is the capacity to modulate MSC differentiation into vascular 
smooth muscle cells (SMCs). To test whether watECFCs had this capacity, we isolated WAT-
resident MSCs (referred to as watMSCs) from the same WAT biopsies from which we obtained 
watECFCs; watMSCs were grown from the CD31- cell fraction that resulted from the MACS 
procedure used to isolated CD31+ watECFCs (Supplemental Figure 2). watMSCs were grown 
until 80% confluence and then routinely passaged. In culture, watMSCs displayed a 
characteristic spindle-shape morphology in culture and were highly homogenous with regards to 
cell surface markers expression: FC showed uniform expression of mesenchymal marker CD90 
(>97%) as well as negligible presence of either endothelial (CD31+) or hematopoietic (CD45+) 
cells (Supplemental Figure 2). The MSC phenotype was confirmed by the ability of watMSCs to 
differentiate into cells from multiple mesenchymal lineages [22]. watMSCs differentiated into 
adipocytes, osteocytes and chondrocytes, as shown by the intracellular accumulation of oil 
droplets (adipogenesis), calcium deposition (osteogenesis) and glycosaminoglycan deposition 
in pellet cultures (chondrogenesis), respectively (Supplemental Figure 2). This multilinage 
differentiation potential was similar to that displayed by bone marrow-derived MSCs (bmMSCs) 
that were isolated from human bone marrow aspirates to serve as controls. Additionally, 
watMSCs were serially passaged (up to P10) to determine their expansion potential. We 
estimated that from 1 g of WAT, 2x109 (accumulated cell number) watMSCs can be obtained in 
approximately 20 days (P4) and as much as 1012 watMSCs in 33 days (P7) (Supplemental 
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Figure 2). This expansion potential was similar to that displayed by bmMSCs isolated from 25 
mL of bone marrow aspirates. 
 
To assess the ability of watECFCs to modulate MSC differentiation into SMCs, we cultured 
them in direct contact with watMSCs that were obtained from the same WAT sample. Cultured 
MSCs   share   multiple   cellular   markers   with   SMCs   (e.g.,   α-SMA, calponin), therefore, 
differentiation was assessed by expression of smooth muscle myosin heavy chain (smMHC), a 
definitive marker of mature SMCs that is not expressed by MSCs. Indeed, in the absence of 
direct contact with ECFCs, smMHC expression was undetectable in watMSCs (Figure 4A). 
However, when watMSCs were directly co-cultured with watECFCs for 7 days, expression of 
smMHC was consistently induced (Figure 4A), indicating smooth muscle myogenic ability. The 
ability of watECFCs to induce MSC differentiation was quantified and found equal (P>0.05) to 
that displayed by both cbECFCs and pbECFCs (Figure 4B). 
 
In vivo vasculogenic potential of WAT-derived ECFCs 
To test blood vessel-forming ability, we used our xenograft mouse model [4]; watECFCs were 
combined with watMSCs and subcutaneously implanted into nude mice for 8 days (Figure 5). 
Histological examination of explants revealed extensive networks of perfused human 
microvessels (Figure 5A-C and online Supplemental Figure 3), confirming the lumenal 
localization of watECFCs. Examination of watECFC-lined vessels showed no histological 
evidence of thrombosis. Microvessel density in implants that contained watECFCs/watMSCs 
(67.62 vessels/mm2) was statistically similar to those containing cbECFCs/bmMSCs (145.12 
vessels/mm2) and pbECFCs/bmMSCs (80.46 vessels/mm2)(P>0.05) (Figure 5D). To confirm 
these histological results, additional implant-bearing mice were injected (i.v.) with rhodamine-
conjugated UEA-1 just before removing the implants (online Supplemental Figure 4); cells were 
then enzymatically retrieved and analyzed by FC. We found that the total number of ECFCs that 
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engrafted as part of a perfused lumen (hCD31+/UEA-1+) was statistically similar in implants that 
contained cbECFCs (2.3x104), pbECFCs (2.2x104), and watECFCs (2.3x104) (Figure 5E) 
(P>0.05). Finally, watECFC-lined microvessels showed equal perivascular coverage than those 
lined by blood-derived ECFCs, which indicated no differences in their ability to form stable 
vessels (Figure 5G-I). 
 
Discussion 
Here, we demonstrated that human WAT is a dependable source of ECFCs with properties 
similar to those obtained from adult peripheral blood, including a robust ability to form functional 
blood vessels in vivo. The feasibility of using human ECs to bioengineer a microvascular 
network that integrates with a host vasculature was first demonstrated with Bcl-2-transduced 
umbilical vein ECs (HUVECs) [23] and juvenile dermal (foreskin) microvascular ECs (HDMECs) 
[24]. However, both HUVECs and HDMECs originate from non-adult tissues and thus, they are 
not readily available for general clinical use. Instead, patients would need to rely on ECs 
obtained from their aged vascular tissues, but the full vasculogenic potential of mature ECs 
have not been systematically assessed in the context of tissue engineering. In this regard, the 
discovery of highly proliferative ECFCs in human peripheral blood created a promising 
opportunity to non-invasively obtain large quantities of readily available, autologous ECs [1,2]. 
Over the last few years, we and others have rigorously demonstrated that human adult ECFCs 
indeed have robust in vivo vasculogenic potential and that when combined with a suitable 
source of perivascular cells (namely, SMCs or MSCs), ECFCs can generate long-lasting, stable 
vascular networks in mice that are more extensive and form more rapidly than those shown in 
earlier reports with other mature ECs [3-7,20]. However, ECFCs are exceedingly rare in adult 
peripheral blood [2,8,9] and there are increasingly more studies recognizing absence of 
pbECFCs in a substantial proportion (~30%) of both healthy and non-healthy adult subjects [10-
 13 
12]. In addition, the mechanism by which ECFCs are mobilized into circulation remains elusive, 
and thus the reliability of peripheral blood as a clinical source of ECFCs is a concern. 
 
In response to this uncertainty, we set up this study to test whether ECFCs can be reliably 
isolated from other alternative human tissue, namely WAT. Previously, Ingram et al. 
demonstrated that the wall of both the aorta and the umbilical vein contain a complete hierarchy 
of highly proliferative ECs with equal colony-forming ability to blood-derived ECFCs [16], but 
whether similar ECFCs are present in human WAT has not been shown to date. To answer this 
question, we adapted a simple procedure that enables isolating ECs from small (1 g) intact 
biopsies of normal subcutaneous WAT (no liposuction aspirates were used) by enzymatic 
digestion followed by selection of CD31+ cells. Subsequently, we extensively interrogated the 
entire WAT-derived EC population, compared it to bonafide blood-derived ECFCs, and 
unequivocally demonstrated that the vasculature of human WAT is indeed a dependable source 
of ECFCs. We showed that WAT has a hierarchical distribution of watECFCs with colony-
forming ability that was consistent with that of adult blood-derived ECFCs [2]. The percentage of 
ECFCs with colony-forming potential (>3 divisions) was 7% and 15% for watECFCs and 
pbECFCs, respectively.  
 
Our study has revealed several characteristics that make WAT an advantageous alternative for 
the obtention of ECFCs. First, unlike adult peripheral blood, WAT was found to be a very 
reliable source of ECFCs, with 100% (5/5) success rate observed in this study. Second, 
watECFC cultures were highly pure (>96%) and the presence of other stromal contaminants 
(namely, hematopoietic or mesenchymal cells) was negligible. Third, watECFCs had remarkable 
expansion potential. We showed that 109 homogeneous watECFCs can be obtained from 1 g of 
WAT after 30 days in culture; this cell number is likely to be sufficient considering what would be 
needed for most cell-based applications. Also, WAT biopsies exceeding 1 g can easily be 
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harvested without increasing morbidity, which would proportionally amplify cell yield. To put this 
into perspective, the replicative capacity we have shown for watECFCs is lower than that 
reported for neonatal cbECFCs but similar to adult pbECFCs [2,3,15]. Fourth, similarly to blood-
derived ECFCs, watECFCs had a stable phenotype. We demonstrated that culture expanded 
watECFCs robustly displayed endothelial properties and functions, as confirmed by (i) the 
expression of EC markers (CD31, VE-cadherin, vWF, eNOS, VEGFR-2); (ii) uptake of Ac-LDL; 
(iii) binding of UEA-1 lectin; (iv) capillary-like network formation ability; (v) response to 
angiogenic growth factors (VEGF, bFGF); and (vi) up-regulation of adhesion molecules (E-
selectin, ICAM-1) upon exposure to TNF-α  and  subsequent  increase  in  leukocyte  binding.  Fifth,  
culture expanded watECFCs had a robust in vivo vasculogenic potential. Without exception, in 
all WAT-derived ECFCs tested, co-implantation with watMSCs into immunodeficient mice 
rapidly generated an extensive network of human blood vessels with watECFCs specifically 
lining the lumens and MSCs occupying perivascular position. Importantly, we found no 
differences between pbECFCs and watECFCs in terms of ability to form microvessels with 
extensive perivascular coverage, as accounted by both FC and histology. Collectively, our study 
has revealed not only that watECFCs were undoubtedly ECs, but also that WAT- and blood-
derived ECFCs were phenotypically highly similar. 
 
Finally, an important additional advantage of WAT is the well-recognized presence of MSCs 
(watMSCs) [6,25], which eliminates the need for bone marrow biopsies in our effort to 
bioengineer microvascular networks. Indeed, we isolated watMSCs from the CD31- cell fraction 
of WAT and demonstrated their similarities with bone marrow-derived MSCs, including (i) 
expansion potential, (ii) multi-lineage differentiation potential, and (iii) ability to modulate ECFC 
function both in vitro and in vivo. Of note, watMSCs were susceptible to undergoing smooth 
muscle myogenic differentiation in the presence of all three types of ECFCs (watECFCs, 
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cbECFCs, and pbECFCs), with no significance difference among any of them. This myogenic 
susceptibility was identical to that of bmMSCs, as previously reported [4]. 
 
In conclusion, we found that human WAT is a reliable source of ECFCs with properties similar to 
those obtained from adult peripheral blood, including a robust ability to form functional blood 
vessels in vivo. For well over a decade, the possibility of obtaining autologous ECFCs from a 
simple blood draw created widespread excitement. However, considering (1) the unreliability 
and low rate of occurrence of ECFCs in adult peripheral blood, (2) our limited understanding of 
how pbECFCs are mobilized into circulation, and (3) the fact that biopsies of WAT can be 
obtained with minimal intervention in an ambulatory setting, we foresee WAT as a more 
practical alternative to obtain large amounts of readily available autologous ECFCs. Further 
studies assessing the clinical potential of watECFCs in aging adults and in health and disease 
are warranted. 
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Figures captions 
 
Figure 1. Isolation and culture expansion of ECFCs from human WAT. (A) Human 
watECFCs were isolated from subcutaneous WAT after enzymatic digestion and were purified 
from the stromal vascular fraction (SVF) using CD31-coated magnetic beads. (B-C) Phase 
contrast   micrographs   of   (B)   a   colony   (scale   bar:   500   μm)   and   (C)   a   confluent   monolayer of 
watECFCs with characteristic cobble-stone   morphology   (scale   bar:   200   μm).   (D)   Expansion  
potential of watECFCs measured by accumulative cell number in serially passaged cells. (E-G) 
Cloning-forming ability of watECFCs was examined at clonal density and compared to cord and 
peripheral blood-derived ECFCs (passage 2). (E) The endothelial nature of the colonies was 
confirmed by binding of UEA-1  lectin  (scale  bar:  500  μm).  (F)  Percentage  of  cells  with  cloning  
ability (>8 cells) after 10 days. (G) Colonies were categorized into large (>300 cells), medium 
(100-300 cells) and small (8-100 cells) size. All bars represent mean ± S.D. from three 
independent   samples.   *   P<0.05   between   watECFCs   and   pbECFCs.   †   P<0.05   between  
watECFCs and cbECFCs. (n.s.) P>0.05 between watECFCs and both pbECFCs and cbECFCs. 
 
Figure 2. Phenotypical characterization of watECFCs. (A) Indirect immunofluorescence of 
watECFCs showed positive staining for CD31, vWF, and VE-cadherin. IgG control depicted in 
inset. Cell nuclei were counterstained   with   DAPI   (scale   bar:   100   μm).   (B)   Flow   cytometry  
analysis of watECFCs for CD31, CD90, and CD45. Black line histograms represent cells stained 
with fluorescent antibodies. Isotype-matched controls are overlaid in solid gray histograms. (C) 
Quantitative RT-PCR analyses of ECFCs for endothelial (CD31, vWF, VE-Cadherin, VEGFR2, 
eNOS)  and  mesenchymal  (CD90,  PDGFRβ)  markers.  (D)  Binding  of  UEA-1 lectin to watECFCs. 
IB4   lectin   served   as   negative   control   (inset)   (scale   bar:   50   μm).   (E)   watECFCs   uptake   of  
fluorescently labeled Ac-LDL (Dil-Ac-LDL)  (scale  bar:  50  μm).  MSCs  served  as  negative  uptake  
control (inset). 
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Figure 3. In vitro functional characterization of watECFCs. (A) Proliferation of ECFCs after 
48 h in response to  VEFG-A (10 ng/mL) and FGF-2 (1 ng/mL). Cell number were normalized to 
those obtained with basal medium. (B) Migration in response to VEGF-A (10 ng/mL) and FGF-2 
(1 ng/mL). Representative micrographs of scratched watECFCs after 24 h in basal and FGF-2-
containing medium (dashed line delineate the scratch;;   scale   bar:   500   μm).   Scratch   size  was  
quantified at 24 h as percentage of original size. (C) Representative micrograph of watECFC-
lined capillary-like network on a Matrigel-coated   plate   (scale   bar:   500   μm).   Total   tube   length  
quantified at 24 h. (D) Up-regulation of E-selectin and ICAM-1 in response to TNF-α.  
Representative flow cytometry histograms depicted for watECFCs. Red line histograms 
represent cells stimulated with TNF-α,  while  solid  gray  histograms  represent  untreated  controls.  
(E) Representative micrographs of watECFC with an increased number of bound HL-60 
leukocytes after TNF-α   treatment   compared   to   untreated   control   (scale   bar:   200   μm).  
Quantification of bound leukocytes per unit of area for each of ECFC group. All bars represent 
mean ± S.D. from  three  independent  samples.  *  P<0.05  between  watECFCs  and  pbECFCs.  †  
P<0.05 between watECFCs and cbECFCs. (n.s.) P>0.05 between watECFCs and both 
pbECFCs and cbECFCs. 
 
Figure 4. Smooth muscle cell differentiation of watMSCs. Smooth muscle myogenic 
differentiation was evaluated by culturing watMSCs in the presence of ECFCs for 7 days. 
Induction of SMC phenotype was assessed by the expression of smMHC (smMHC-FITC). 
Expression of vWF (vWF-Texas Red) was used to detect ECFCs and DAPI for cell nuclei. (A) 
Representative immunofluorescent images of watMSCs in the absence or presence of various 
types of ECFCs. smMHC was absent in monocultures of watMSCs (left panel), but it was 
induced when co-cultured  with  watECFCs,  cbECFCs,  and  pbECFCs   (scale  bar:  100  μm).   (B) 
Quantification of smooth muscle myogenic differentiation as number of MSCs expressing 
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smMHC per unit of culture area. All bars represent mean ± S.D. from three independent 
samples. (n.s.) P>0.05 between watMSCs and bmMSCs and between all three types of ECFCs. 
 
Figure 5. In vivo vasculogenic potential of watECFCs. ECFCs were combined with MSCs in 
collagen-fibrin gel and the mixture subcutaneously injected into nude mice for 8 days. (A) H&E 
from one representative watECFC explant (inset, scale bar: 5 mm) with numerous blood vessels 
(yellow  arrowheads;;  scale  bar:  50  μm).   (B-C) Immunohistochemistry (hCD31) showed human 
specific  lumens  (yellow  arrowheads;;  scale  bars:  50  μm).  (D)  Microvessel  density  determined  as  
luminal structures containing erythrocytes. (E) Rhodamine-conjugated UEA-1 was injected (i.v.). 
10 min before implants were excised. The number of ECFCs that were part of a perfused lumen 
(hCD31+/UEA-1+) was quantified by FACS. (F) hCD31 (green) immunofluorescent staining of a 
representative UEA-1+ (red)   microvessel   in   a   watECFC   explant   (scale   bar:   20   μm).   (G-H) 
Perivascular coverage was assessed by double immunofluorescent staining of explants with 
UEA-1   (red)   and   α-smooth   muscle   actin   (α- SMA; green). Images are representative of all 
watECFC explants. Nuclei  were  counterstained  with  DAPI  (scale  bars:  50  μm).  (I)  Percentage  of  
human UEA-1+ blood  vessels  covered  by  α-SMA+ perivascular cells. Human dermis served as 
control. All bars represent mean ± S.D. from three independent samples. * P<0.05 between 
watECFCs  and  pbECFCs.  †  P<0.05  between  watECFCs  and  cbECFCs.  (n.s.)  P>0.05  between  
watECFCs and both pbECFCs and cbECFCs. 
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SUPPLEMENTAL MATERIAL
DETAILED METHODS 
Isolation of ECFCs and MSCs from white adipose tissue (WAT)
Normal discarded subcutaneous WAT samples (n=5) were obtained during a clinically-indicated 
procedure in accordance with an Institutional Review  Board-approved protocol. WAT samples 
were washed, minced and enzymatically (collagenase and dispase) digested for 1h at 37°C. 
The stromal vascular fraction (SVF) was obtained after removal of mature adipocytes by 
centrifugation (450xg for 10 min) and the lysis of erythrocytes with ammonium chloride solution 
[1]. watECFCs were purified by magnetic activated cell sorting (MACS) using CD31-coated 
magnetic beads (Dynalbeads; Invitrogen, Grand Island, NY). CD31-selected watECFCs were 
cultured on 1% gelatin-coated plates using ECFC-medium: EGM-2 (except for hydrocortisone; 
Lonza, Walkersville, MD) supplemented with 20% FBS (Atlanta Biological, Lawrenceville, GA), 
1x glutamine-penicillin-streptomycin (GPS; Invitrogen, Carlsbad, CA). watMSCs were obtained 
from the CD31- cell fraction of  the SVF and were cultured onto non-coated plates using MSC-
medium: MSCGM Mesenchymal Stem Cell Medium BulletKit (basal media and SingleQuots; 
Lonza), supplemented with 10 % FBS (MSC-Qualified; Invitrogen), 1xGPS (Invitrogen), and 10 
ng/mL of FGF-2 (R&D Systems, Minneapolis, MN).
Isolation of ECFCs from blood
Human blood samples were obtained in accordance with Institutional Review  Board-approved 
protocols. Blood-derived ECFCs were obtained as previously described [2,3]. Briefly, ECFCs 
were isolated from the mononuclear cell (MNC) fractions, after Ficoll-Paque (GE Healthcare, 
Pittsburgh, PA) density gradient centrifugation, of  both cord blood (cbECFCs) and adult 
peripheral blood (pbECFCs) samples, and purified using CD31-coated magnetic beads. ECFCs 
were cultured on 1% gelatin-coated plates using ECFC-medium. 
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Isolation of MSCs from bone marrow
Human bmMSCs were isolated from the MNC fraction of 25 mL bone marrow  aspirates samples 
(Lonza) after Ficoll-Paque density gradient centrifugation, as previously described [3]. MNCs 
were seeded on non-coated tissue culture plates using MSC-medium. Unbound cells were 
removed at 48 hours, and the bound cell fraction maintained in culture until 70% confluence 
using MSC-medium.
Expansion potential
watECFCs were expanded for 50 days. All passages were performed by plating the cells onto 
1% gelatin-coated tissue culture plates at 5x103 cell/cm2 using ECFC-medium. watMSCs and 
bmMSCs were expanded for 50 days, and all the passages were performed by plating the cells 
onto non-coated tissue culture plates at 104 cell/cm2 using MSC-medium. Medium was 
refreshed every 2 to 3 days and cells were harvested by trypsinization and replated in the same 
culture conditions for the next passage. Cumulative values of  total cell number were calculated 
by counting the cells at the end of each passage using a hemocytometer.
Colony-forming assay
Passage 2 (P2) ECFCs were culture for 10 days at clonal density (200 cell/60 cm2; 600 cells 
plated; n=3 per ECFC type) onto 1% gelatin-coated plates using ECFC-medium. Medium was 
refreshed every 4 days. At day 10, colonies containing 8 or more cells (i.e., at least 3 divisions) 
were scored under a fluorescence microscope after DAPI staining of the nuclei. Endothelial 
phenotype was confirmed by binding of  rhodamine-labeled Ulex Europaeus Agglutinin I (UEA-1; 
1:100; Vector Laboratories, Burlingame, CA) using a fluorescent microscope. Colonies were 
categorized into large (>300 cells), medium (100-300 cells) and small (8-100 cells) size. The 
number of cells in each colony was quantified under a fluorescent microscope after DAPI 
staining using ImageJ analysis software (NIH, Bethesda, MD, USA).
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Flow cytometry
Cytometric analyses were carried out by labeling with phycoerythrin (PE)-conjugated mouse 
anti-human CD31 (Ancell, Bayport, MN), PE-conjugated mouse anti-human CD90 (BD 
Biosciences, San Jose, CA), fluorescein isothiocyanate (FITC)-conjugated mouse anti-human 
CD45 (BD Biosciences), FITC-mouse IgG1 (BD Biosciences), and PE-mouse IgG1 (BD 
Biosciences) antibodies (1:100). Antibody labeling was carried out for 20 min on ice followed by 
3 washes with 1% BSA, 0.2 mM EDTA in PBS and resuspension in 1% paraformaldehyde in 
PBS. Flow  cytometric analyses were performed using a Guava easyCyte 6HT/2L flow  cytometer 
(Millipore Corporation, Billerica, MA) and FlowJo software (Tree Star Inc., Ashland, OR). Human 
mesenchymal stem cells (MSCs) served as controls. 
Indirect immunofluorescence
Immunofluorescence was carried out using mouse anti-human CD31 (1:200;   DakoCytomation, 
Carpinteria, CA), mouse anti-human vWF (1:200; DakoCytomation), and goat anti-human VE-
cadherin (1:200; Santa Cruz Biotechnology, Santa Cruz, CA) antibodies, followed by FITC-
conjugated secondary antibodies (1:200; Vector Laboratories) and Vectashield mounting 
medium with DAPI (Vector Laboratories). Human MSCs served as controls. 
RT-PCR and multigene transcriptional profiling
Total RNA was isolated with a RNeasy kit (QIAGEN, Valencia, CA), and cDNA was prepared 
using reverse transcriptase III (Invitrogen). Multigene transcriptional profiling was used to 
determine the number of mRNA copies per cell normalized to 18S rRNA abundance (~106 18S-
rRNA copies/cell) [4]. Real-time PCR primer sequences were as follows: human CD90 (hCD90; 
Thy1) (F:GCCTAACGGCCTGCCTAGT, R:GGGTGAACTGCTGGTATTCTCAT); human CD31 
(hCD31; PECAM1) (F:CACCTGGCCCAGGAGTTTC, R:AGTACACAGCCTTGTTGCCATGT); 
human vWF (hvWF) (F:GTCGAGCTGCACAGTGACATG, R:GCACCATAAACGTTGACTTCCA); 
human VE-Cadherin (VE-Cad.; CD144) (F:GAACCCAAGATGTGGCCTTTAG, R: ATGTGACAA-
3
CAGCGAGGTGTAA); human VEGFR2 (F:GGCAAATGTGTCAGCTTTGTACA, R: GTCACGTG-
GAAGGAGATCAC); human eNOS (NOS3) (F:AGATCTCCGCCTCGCTCAT, R:GTCTCGGAGC-
CATACAGGATTG); human PDGFRβ (CD140b)(F:GGTGGGCACACTACAATTTGC,  R:GGTG-
GGTAGGCCTCGAACA).
Binding of Ulex Europaeus Agglutinin lectin
Confluent monolayers of  ECFCs were incubated with rhodamine-labeled UEA-1 (Vector 
Laboratories; final concentration: 20 µg/mL) in ECFC-medium for 30 min. Cells were washed 
three times in ECFC-medium, fixed in 4% paraformaldehyde in PBS and cell nuclei stained with 
DAPI. Cells were visualized under a fluorescent microscope.
Uptake of Ac-LDL
Confluent monolayers of ECFCs were incubated with DiI-Ac-LDL (Invitrogen; final concentration: 
5 µg/mL) in ECFC-medium for 8 h. Cells were washed three times in ECFC-medium, fixed in 
4% paraformaldehyde in PBS and cell nuclei stained with DAPI. Cells were visualized under a 
fluorescent microscope.
Proliferation assay
ECFCs were seeded in triplicate onto fibonectin-coated 24-well plates at 5x103 cell/cm2 using 
basal medium (EBM-2, 5% FBS). Plating efficiency was determined at 24 h. Cells were then 
treated for 48 h using basal medium in the presence or absence of either 10 ng/mL VEGF-A or 1 
ng/mL FGF-2 (R&D Systems). Cells were quantified under a fluorescent microscope after DAPI 
staining using ImageJ analysis software; results were normalized to cell number obtained in 
basal medium.
Scratch assay
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The scratch assay was performed in confluent cultures of ECFCs plated on 6-well plates. 
Scratch wounds were generated across each well using a pipette tip. Cells were then treated for 
24 h using basal medium in the presence or absence of  10 ng/mL VEGF-A or 1 ng/mL FGF-2. 
Scratch size was measured after 24 h under a phase contrast microscope.
Tube formation assay
ECFCs were seeded on Matrigel-coated plates at a density of  2x104 cell/cm2 and incubated for 
24 h in ECFC-medium. The total length of  ECFC-lined cords were measured using ImageJ 
analysis software.
Up-regulation of leukocyte adhesion molecules
ECFC monolayers were challenged with or without 10 ng/ml of  tumor necrosis factor-α (TNF-α; 
R&D Systems) for 5 h. Afterwards, the leukemia cell line HL-60 (2x106 cells) was added and 
incubated at 4°C on a rocking platform for 45 min. Bound leukocytes were visualized using a 
phase contrast microscope and quantified with ImageJ analysis software. Additionally, leukocyte 
adhesion molecules were analyzed by flow  cytometry using PE-conjugated antibodies against 
human E-selectin and ICAM-1 (1:100; BD Biosciences).
Adipogenic differentiation of MSCs
Confluent MSCs were cultured for 10 days in low-glucose DMEM with 10 % FBS, 1x GPS, and 
ad ipogenic supplements (5 µg/mL insu l in , 1 µM dexamethasone, 0 .5 mM 
isobutylmethylxanthine, 60 µM indomethacin, 1 µM rosiglitazone). Differentiation into adipocytes 
was assessed by Oil Red O staining. Cells cultured in medium lacking adipogenic supplements 
served as a negative control.
Osteogenic differentiation of MSCs
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Confluent MSCs were cultured for 21 days in low-glucose DMEM with 10 % FBS, 1x GPS, and 
osteogenic supplements (1 µM dexamethasone, 10 mM β-glycerophosphate, 60 µM ascorbic 
acid-2-phosphate). Differentiation into osteocytes was assessed by Alizarin Red and von Kossa 
staining. Cells cultured in medium lacking osteogenic supplements served as a negative control.
Chondrogenic differentiation of MSCs
Suspensions of MSCs were gently centrifuged in 15 mL polypropylene centrifuge tubes 
(500,000 cells/tube). The pellets were cultured in high-glucose DMEM medium with 1x GPS, 
and chondrogenic supplements (1x insulin–transferrin–selenium, 1 µM dexamethasone, 100 µM 
ascorbic acid-2-phosphate, and 10 ng/mL TGF-β3). After 21 days, pellets were fixed in 10 % 
buffered formalin, cryoprotected in 30 % (w/v) sucrose solution, embedded in O.C.T. medium, 
and sectioned (8 µm-thick) using a cryostat microtome. Differentiation into chondrocytes was 
assessed by evaluating the presence of glycosaminoglycans after Alcian Blue staining. Cells 
cultured in the absence of TGF-β3 served as negative controls and failed to form compact 
spheroids.
Smooth muscle myogenic differentiation of MSCs
MSCs were co-cultured for 7 days with ECFCs (1:1 ratio) on fibonectin-coated, 2-well Permanox 
chamber slides at a density of 105 cell/well using ECFC-medium. MSC expression of smooth 
muscle myosin heavy chain (smMHC) was evaluated by immunofluorescence using a rabbit 
monoclonal antibody (1:200; Biomedical Technologies, Stoughton, MA) followed by anti-rabbit 
FITC-conjugated secondary antibody (1:200; Vector Laboratories). ECFCs were stained with 
mouse anti-human vWF (1:200; DakoCytomation) followed by Texas Red-conjugated secondary 
antibody (1:200; Vector Laboratories). Monocultures of MSCs cultured in ECFC-medium served 
as negative control. Quantification was carried out in numerous regions from replicated cultures 
by enumerating the number of smMHC-expressing MSCs per unit of area. 
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in vivo vasculogenic assay
Six-week-old athymic nu/nu mice were purchased from Massachusetts General Hospital 
(Boston, MA). Mice were housed in compliance with Boston Children’s Hospital guidelines, and 
all animal-related protocols were approved by the Institutional Animal Care and Use Committee. 
Vasculogenesis was evaluated in vivo using our xenograft model as previously described [5]. 
Briefly, ECFCs and MSCs (2x106 total; 2:3 ECFC/MSC ratio) were resuspended in 200 µl of 
collagen/fibrin–based solution (3 mg/mL of bovine collagen, 30 ug/mL of human fibronectin, 
25mM HEPES, 10% 10x DMEM, 10% FBS, and 3 mg/mL of  fibrinogen, pH neutral). Before cell 
injection, 50 uL of  10 U/mL thrombin was subcutaneously injected. All experiments were carried 
out in 4 mice.
Histology and immunohistochemistry
Implants were removed from euthanized mice, fixed in 10% buffered formalin overnight, 
embedded in paraffin, and sectioned (7-µm-thick). Hematoxylin and eosin (H&E) stained 
sections were examined for the presence of blood vessels containing red blood cells. For 
immunohistochemistry, sections were deparaffinized, and antigen retrieval was carried out by 
heating the sections in Tris-EDTA buffer (10 mM Tris-Base, 2 mM EDTA, 0.05% Tween-20, pH 
9.0). The sections were blocked for 30 min in 5-10% blocking serum and incubated with primary 
antibodies for 1h at RT. The following primary antibodies were used: mouse anti-human CD31 
(1:50; DakoCytomation, M0823 Clone JC70A), mouse anti-human α-SMA (1:200; Sigma-
Aldrich, A2547 Clone 1A4), and mouse IgG (1:50; DakoCytomation). Horseradish peroxidase 
(HRP)-conjugated mouse secondary antibody (1:200; Vector Laboratories) and 3,3’-
diaminobenzidine (DAB) were used for detection of  hCD31, followed by hematoxilin 
counterstaining and Permount mounting. Fluorescent staining were performed using rhodamine-
conjugated UEA-1 (20 µg/mL) and FITC-conjugated secondary antibodies (1:200; Vector 
Laboratories) followed by DAPI counterstaining. 
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Microvessel density
Microvessel density was reported as the average number of erythrocyte-filled vessels (vessels/
mm2) in sections from the middle of the implants as previously described [2]. The entire area of 
each section was analyzed. Values reported for each experimental condition correspond to 
mean ± S.D. obtained from four individual mice. 
Quantification of lumenal ECFCs in vivo
Rhodamine-conjugated UEA-1 (100 uL; 1 mg/mL in normal saline) was intravenously injected 
into the tail vein of implant-bearing mice 10 min before harvesting the implants at day 8. 
Implants were removed from euthanized mice, enzymatically (collagenase and dispase) 
digested for 1 h at 37°C, and the retrieved cells analyzed by FACS after incubation with PerCP-
conjugated anti-mouse CD45 (1:100; BD Biosciences), APC-conjugated anti-human CD90 
(1:100; BD Biosciences), and FITC-conjugated anti-human CD31 antibodies (1:100; BD 
Biosciences). ECFCs in each implant were identified as mCD45-/hCD31+ cells. Perfused ECFCs 
were identified as mCD45-/hCD31+/UEA-1+ cells.
Microscopy
All images were taken with an Axio Observer Z1 inverted microscope (Carl Zeiss, Berlin, 
Germany) using AxioVision Rel. 4.8 software. Phase microscopy images were taken with an 
AxioCam MRm camera and 5x/0.16 or 10x/0.3 objective lens. All fluorescent images were taken 
with an ApoTome.2 Optical sectioning system (Carl Zeiss) and 20x/0.8 or 40x/1.4 oil objective 
lens. Non-fluorescent images were taken with an AxioCam MRc5 camera using a 40x/1.4 
objective oil lens.
Statistical analysis
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Data were expressed as mean ± S.D. Comparisons between groups were performed by 
ANOVA followed by Tukey’s multiple post-test analysis using Prism Version 4 software 
(GraphPad). P<0.05 was considered statistically significant.
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SUPPLEMENTAL FIGURES
Supplemental Figure 1. Phenotypical and functional characterization of ECFCs. (A) Flow 
cytometry analysis of ECFCs for EC marker CD31, mesenchymal marker CD90, and 
hematopoietic marker CD45. Black line histograms represent cells stained with fluorescent 
antibodies. Isotype-matched controls are overlaid in solid gray histograms. (B) Indirect 
immunofluorescence of ECFCs grown in a confluent monolayer showing positive staining for 
CD31, vWF, and VE-cadherin. Mouse IgG was used as control. Cell nuclei were counterstained 
with DAPI (scale bar: 100 µm). (C) Binding of  UEA-1 lectin to a monolayer of ECFCs. IB4 lectin 
served as negative control (inset) (scale bar: 50 µm). (D) ECFCs uptake of fluorescently labeled 
acetylated-low  density lipoproteins (Dil-Ac-LDL) (scale bar: 50 µm). MSCs served as negative 
uptake control (inset). (E) Up-regulation of E-selectin and ICAM-1 in cultured ECFCs in 
response to TNF-α. Black line histograms represent cells stimulated with TNF-α, while solid gray 
histograms represent untreated controls.
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Supplemental Figure 2. Isolation and culture expansion of MSCs from human WAT. (A) 
Human watMSCs were isolated from subcutaneous WAT after enzymatic digestion and were 
selected as CD31- cells from the stromal vascular fraction (SVF). (B) Phase contrast 
micrographs of watMSCs and bmMSCs with characteristic spindle-shape morphology (scale 
bar: 100 µm). (C) Flow  cytometry analysis of watMSCs and bmMSCs for CD31, CD90, and 
CD45. Black line histograms represent cells stained with fluorescent antibodies. Isotype-
matched controls are overlaid in solid gray histograms. (D) Multilineage differentiation of MSCs 
in vitro. Differentiation into adipocytes was revealed by oil red O staining (scale bar 100 µm). 
Differentiation into osteocytes was revealed by Alizarin Red staining and von Kossa staining for 
calcium deposition and mineralization (scale bar 100 µm). Insets represent MSCs in non-
differentiating control medium. Chondrogenic differentiation was revealed in pellet culture by the 
presence of glycosaminoglycans, detected by Alcian blue staining (scale bar 200 µm). (E) 
Expansion potential of watMSCs and bmMSCs measured by accumulative cell number in 
serially passaged cells.
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Supplemental Figure 3. In vivo vasculogenic potential. ECFCs were combined with MSCs 
and the mixture subcutaneously injected into nude mice (n=4) using collagen/fibrin-based gel. 
(A) H&E at day 8 from representative ECFC explants with numerous blood vessels containing 
RBCs (yellow  arrowheads; scale bar: 50 µm). Inset represent the macroscopic views of  the 
explants (scale bar: 5 mm). (B) hCD31 immunohistochemistry showed human specific lumens 
(yellow  arrowheads; scale bars: 50 µm). (C) Perivascular coverage was assessed by double 
immunofluorescent staining of  explants with UEA-1 (red) and α-SMA (green). Images are 
representative of all ECFC explants. Nuclei were counterstained with DAPI (scale bars: 50 µm).
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Supplemental Figure 4. Quantification of lumenal ECFC engraftment by UEA-1 injection 
and FACS. (A) Schematic diagram. To quantify lumenal engraftment, ECFCs/MSCs were 
implanted into nude mice. After 8 days, rhodamine-conjugated UEA-1 was injected (i.v.). and 10 
min later the implants were excised and enzymatically digested. The number of ECFCs that 
were part of a perfused lumen (hCD31+/UEA-1+) was quantified by FACS. (B) FACS gating 
strategy. Human ECFCs (mCD45-/hCD90low/hCD31+) were analyzed for rhodamine-conjugated 
UEA-1 binding. hCD31+/UEA-1+ cells were identified as perfused human ECFCs. Human MSCs 
(mCD45-/hCD90high/hCD31-) served as negative binding control.
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